Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
SIX:BSLN
Price:
41.2 CHF
1.23%
Updated:
May 8, 2024
Basilea Pharmaceutica AG
Cash from Operating Activities
|
Basilea Pharmaceutica AG
Cash from Operating Activities Peer Comparison
Comparables:
ADCT
ACIU
CRSP
IDIA
KURN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Operating Activities
CHf14.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Operating Activities
-$118.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash from Operating Activities
-CHf60.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Operating Activities
-$260.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash from Operating Activities
-CHf859.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Operating Activities
-CHf8.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
See Also
What is Basilea Pharmaceutica AG's Cash from Operating Activities?
Cash from Operating Activities
14.2m
CHF
14.2m
CHF
Based on the financial report for Dec 31, 2023, Basilea Pharmaceutica AG's Cash from Operating Activities amounts to 14.2m CHF.
What is Basilea Pharmaceutica AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
102%
102%
Over the last year, the Cash from Operating Activities growth was 102%.
You don't have any saved screeners yet
